Basit Abdul, Noreen Nuzhat, Saleem Syed Fawad, Yousuf Muhammad, Zafar Faisal
Department of Pediatric Neurology, The Children's Hospital and Institute of Child Health, Multan, PAK.
Department of Pediatric Neurlogy, The Children's Hospital and Institute of Child Health, Multan, PAK.
Cureus. 2022 Mar 14;14(3):e23164. doi: 10.7759/cureus.23164. eCollection 2022 Mar.
Infantile spasm (IS) is an epileptic syndrome characterized by epileptic spasms, hypsarrhythmia on electroencephalography (EEG), and high risk of neurodevelopmental regression. This study was done to compare the efficacy and safety of the high versus the usual dose in children with IS.
This open label randomized controlled trial was conducted at Department of Pediatric Neurology, The Children's Hospital & Institute of Child Health, Multan, Pakistan, from January 1, 2020 to December 31, 2020. A total of 62 children (31 in each group) aged three months to two years presenting with epileptic spasms (at least one cluster per day) with EEG evidence of hypsarrhythmia were included. All 62 children were randomized to receive either high-dose prednisolone (10mg per dose four times a day) or the usual-dose prednisolone (2mg/kg/day thrice a day) for 14 days. Primary outcome measure was noted in terms of proportion of children who achieved complete, partial, or no response. Secondary outcome measure was proportion of children with adverse effects.
In a total of 62 children, there were 34 (54.8%) male. Overall, mean age was noted to be 9.1±3.4 months. The most common etiology of IS was noted to be hypoxic-ischemic encephalopathy (HIE) in 28 children (45.2%). Significantly better clinical efficacy was reported in high-dose prednisolone group when compared to low-dose prednisolone cases as complete response, partial response and no response were noted in nine (29.0%), eight (25.8%), and 14 (45.2%) patients of low-dose group versus 18 (58.1%), eight (25.8%), and five (16.1%) patients in high-dose group, respectively (p=0.0265). Weight gain was the most frequently reported adverse effects noted in 11 (17.7%) cases. Overall, no statistically significant difference in the frequency of adverse effects (p=0.9573).
In comparison to low-dose prednisolone, high-dose prednisolone was found to be significantly more efficacious among cases of IS. Adverse effect in both treatment groups were relatively low and similar.
婴儿痉挛症(IS)是一种癫痫综合征,其特征为癫痫性痉挛、脑电图(EEG)显示高峰失律,且神经发育倒退风险高。本研究旨在比较高剂量与常规剂量治疗IS患儿的疗效和安全性。
本开放标签随机对照试验于2020年1月1日至2020年12月31日在巴基斯坦木尔坦儿童医院及儿童健康研究所儿科神经科进行。共纳入62例年龄在3个月至2岁、出现癫痫性痉挛(每天至少一组)且EEG有高峰失律证据的儿童。62例儿童被随机分为接受高剂量泼尼松龙(每次10mg,每日4次)或常规剂量泼尼松龙(2mg/kg/天,每日3次)治疗14天。主要结局指标根据达到完全缓解、部分缓解或无缓解的儿童比例来记录。次要结局指标是出现不良反应的儿童比例。
62例儿童中,男性34例(54.8%)。总体而言,平均年龄为9.1±3.4个月。IS最常见的病因是28例(45.2%)的缺氧缺血性脑病(HIE)。与低剂量泼尼松龙组相比,高剂量泼尼松龙组的临床疗效显著更好,低剂量组完全缓解、部分缓解和无缓解的患者分别为9例(29.0%)、8例(25.8%)和14例(45.2%),而高剂量组分别为18例(58.1%)、8例(25.8%)和5例(16.1%)(p=0.0265)。体重增加是最常报告的不良反应,有11例(17.7%)。总体而言,不良反应发生率无统计学显著差异(p=0.9573)。
与低剂量泼尼松龙相比,高剂量泼尼松龙在IS病例中疗效显著更好。两个治疗组的不良反应相对较低且相似。